Walleye Capital LLC Acquires New Position in Xenon Pharmaceuticals Inc. $XENE

Walleye Capital LLC acquired a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 76,955 shares of the biopharmaceutical company’s stock, valued at approximately $4,645,000.

Several other institutional investors have also added to or reduced their stakes in the business. Danske Bank A S bought a new position in Xenon Pharmaceuticals during the third quarter worth about $32,000. Kestra Advisory Services LLC bought a new stake in shares of Xenon Pharmaceuticals in the fourth quarter valued at approximately $33,000. Osaic Holdings Inc. raised its position in shares of Xenon Pharmaceuticals by 541.4% in the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,034 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at approximately $43,000. Finally, Rockefeller Capital Management L.P. lifted its stake in shares of Xenon Pharmaceuticals by 450.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,100 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 900 shares in the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. Wall Street Zen upgraded Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Royal Bank Of Canada cut their price target on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Monday, July 6th. Finally, Needham & Company LLC reduced their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Xenon Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $77.13.

Xenon Pharmaceuticals Trading Down 2.9%

XENE stock opened at $62.35 on Friday. The firm has a 50 day moving average of $61.34 and a 200-day moving average of $54.99. Xenon Pharmaceuticals Inc. has a 12 month low of $35.60 and a 12 month high of $72.66. The firm has a market capitalization of $6.03 billion, a P/E ratio of -13.15 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.05. During the same quarter in the previous year, the firm posted ($1.07) EPS. Sell-side analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current year.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the transaction, the director directly owned 1,455 shares of the company’s stock, valued at $77,318.70. This trade represents a 44.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gary Patou sold 1,322 shares of the business’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the transaction, the director owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 12,512 shares of company stock valued at $774,088 in the last three months. Company insiders own 2.91% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.